Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) by 7,500 shares on February 12, with a total net reduction of 60,300 shares over the past five trading days and 210,300 shares over the past twenty trading days [1] - As of now, southbound funds hold 5,645,200 shares of Gaoshi Medical, accounting for 3.81% of the company's total issued ordinary shares [1] Group 2 - Gaoshi Medical Technology Co., Ltd. primarily engages in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [1] - The company operates through four segments: self-owned products, distribution, technical services, and others [1] - The self-owned products segment develops and produces surgical equipment and related software, intraocular lenses, diagnostic and treatment equipment for eye diseases, and related consumables [1] - The distribution segment sells multifunctional diagnostic equipment, fundus diagnostic, surgical, and treatment equipment produced by other ophthalmic medical device manufacturers, along with related consumables [1] - The technical services segment provides warranty, maintenance, and after-sales services along with consumables used for these services [1] - The other segment mainly includes granting intellectual property rights and providing clinical research organization-related services [1]

Core Viewpoint - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 601,000 shares on February 12, indicating a positive sentiment towards the company despite some days of net reductions in holdings [1] Group 1: Southbound Fund Activity - Over the past five trading days, there were two days of net reductions in holdings, totaling 2,280,500 shares [1] - In the last 20 trading days, southbound funds increased their holdings on 15 days, with a total net increase of 23,386,700 shares [1] - Currently, southbound funds hold 924 million shares of MicroPort Medical, accounting for 48.19% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]

Core Viewpoint - TFX is undergoing a significant strategic adjustment announced in December 2025, which is expected to continue into 2026 [1] Group 1: Company Project Progress - TFX announced the sale of its emergency care, interventional urology, and OEM businesses for $2.03 billion, with board approval and expected completion in the second half of 2026, subject to regulatory approvals [2] - The company anticipates a post-tax net gain of approximately $1.8 billion from the transaction, which will be used to optimize its capital structure [2] Group 2: Fund Movements - In conjunction with the business sale, TFX's board approved a stock repurchase plan of up to $1 billion, primarily funded by the proceeds from the sale, aimed at enhancing shareholder returns [3] Group 3: Strategic Advancement - Following the divestiture of non-core businesses, TFX will focus more on high-growth areas such as vascular access, interventional, and surgical sectors [4] - The integration effects of the previously announced acquisition of the BodiLink vascular intervention business (approximately €760 million) will also be closely monitored, as it may impact mid- to long-term performance [4]

Core Viewpoint - ResMed (RMD.N) faces potential drug competition from Apnimed's oral obstructive sleep apnea (OSA) medication AD109, which could disrupt its market dominance in the OSA device sector [1] Industry Position - ResMed holds a dominant position in the global OSA device market, capturing 50%-60% market share, primarily relying on CPAP (Continuous Positive Airway Pressure) devices and masks, utilizing a "razor-and-blades" business model [2] Recent Events - Drug Competition Threat: AD109 is an oral combination tablet taken once daily that improves OSA by maintaining upper airway muscle tone. Phase III trials showed a 47% reduction in the apnea-hypopnea index (compared to 7% in the placebo group) with no serious safety issues. If approved by the FDA, it could be available as early as 2027, offering a more convenient treatment option than devices [3] - Patient Compliance Issues: Current CPAP device compliance is only 20%-30% due to noise and discomfort, while the oral medication may attract the nearly 1 billion untreated OSA patients, of whom less than 20% currently receive treatment. If AD109 is successfully launched, it could divert new patients from ResMed, particularly those with mild to moderate OSA, although severe cases may still require device treatment [3] Performance and Operations - Recent Performance Resilience: In Q2 of FY2026 (ending December 31, 2025), ResMed reported an 11% year-over-year revenue increase to $1.4 billion, with a gross margin improvement to 61.8%, reflecting supply chain optimization and product innovation (e.g., AI-driven tools, compact masks) [4] - Strategic Defense: Management highlighted the positive impact of GLP-1 drugs on CPAP compliance during the earnings call and mentioned strategies such as acquisitions or combination therapies (devices + drugs) to counter potential competition. The company maintains strong cash flow (operating cash flow of $340 million in Q2) and low debt levels, indicating a capacity for transformation [4] - Long-term Market Potential: The prevalence of OSA is expected to continue rising (projected 35% increase in the U.S. by 2050), with a large population of untreated patients, suggesting that drugs and devices may coexist rather than completely replace one another [4] Stock Recent Trends - Stock Price Fluctuation: From February 9 to 12, 2026, ResMed's stock price fell from $275.33 to $246.69 (a cumulative decline of 10.4%), partly due to market concerns regarding the potential threat from AD109 [5] - Key Risks: The FDA approval timeline for AD109 (expected in 2026-2027) is a critical variable; if approved, it could lead to a valuation adjustment for ResMed. Additionally, if ResMed fails to innovate or acquire in a timely manner to offset the threat, its long-term market share may be at risk [5]

Core Viewpoint - Jiangsu Kangzhong Digital Medical Technology Co., Ltd. has announced the first grant of stock options to incentive objects, with a total of 4 million stock options to be granted at an exercise price of 42.38 yuan per share, effective from February 12, 2026 [1][4][6]. Summary by Sections Incentive Plan Details - The stock option incentive plan was approved by the board on February 12, 2026, and involves granting 4 million stock options to 50 qualified incentive objects [1][4]. - The exercise price for the stock options is set at 42.38 yuan per share [9]. Decision-Making Process - The decision-making process included multiple board meetings and a public notice period from January 13 to January 22, 2026, during which no objections were raised [2][3]. - The board confirmed that all necessary approvals and disclosures were completed prior to the grant [2][25]. Eligibility Criteria - The board confirmed that both the company and the incentive objects met all eligibility criteria as outlined in relevant regulations, including no recent disqualifications or legal issues [3][5][17]. - The incentive objects include company directors, senior management, core technical personnel, and other key employees, excluding independent directors [18]. Accounting Treatment and Performance Impact - The accounting treatment for the stock options will follow the guidelines set forth in the relevant accounting standards, with the fair value of the options determined using the Black-Scholes model [20][23]. - The implementation of this incentive plan is expected to positively impact the company's operational performance by enhancing employee motivation and efficiency [24][25].

Group 1 - Shenzhen has reached a milestone with over 600 listed companies, including 426 domestic and 174 overseas, with a total market capitalization exceeding 19 trillion yuan as of January 2026 [1] - The history of Shenzhen's listed companies reflects the evolution of China's modern corporate system, starting from the first stock issued in Bao'an in 1983 [2] - The establishment of the SME Board in 2004 and the Growth Enterprise Market in 2009 opened capital channels for private technology enterprises, with Shenzhen companies occupying significant positions [3] Group 2 - Recent years have seen a new wave of companies redefining "Shenzhen speed," with notable listings such as Yuntian Lifei and Youbixuan, showcasing rapid growth and innovation [4] - New companies listed on the Science and Technology Innovation Board and the Growth Enterprise Market indicate Shenzhen's proactive embrace of capital market reforms and alignment with cutting-edge technology [5] - In the first three quarters of 2025, Shenzhen-listed companies achieved a total revenue of 5.20 trillion yuan and a net profit of 457.8 billion yuan, reflecting strong growth in the manufacturing sector [7] Group 3 - The Hong Kong market has seen significant activity, with 27 new companies raising a total of 29.57 billion HKD, and over 70% of these companies experiencing stock price increases on their first trading day [7] - The strong performance of companies like BYD, which raised over 43.5 billion HKD in a single refinancing, highlights the robust capital market environment in Shenzhen [7] - Shenzhen's high-tech exports, including drones and 3D printers, grew by 10.1% in 2025, supported by a solid foundation of national high-tech enterprises [7] Group 4 - The journey from the first stock in 1983 to 600 listed companies today illustrates Shenzhen's transformation from a pilot city to a benchmark for capital markets in China [8] - Each listed company represents a milestone for Shenzhen, indicating that reaching 600 is not an endpoint but a new starting point for further growth [8]

Group 1 - Shenzhen's listed companies are experiencing a surge in "new quality productivity" focused on hard technology and future industries, with R&D investment nearly doubling during the 14th Five-Year Plan period, reaching 210.3 billion yuan in 2024, a 91.35% increase from 2020 [1] - In the first three quarters of 2025, disclosed R&D expenses totaled 156.33 billion yuan, marking a historical high with a year-on-year growth of 11.59%, significantly outpacing the national average [1] - Approximately 80% of newly listed companies are from the Sci-Tech Innovation Board and the Growth Enterprise Market, with a total of 216 companies, representing over half of A-share Shenzhen enterprises, leading among major cities in China [1] Group 2 - A notable "innovation matrix" has formed in Shenzhen, with companies like UBTECH Robotics, Youjia Innovation, and SUTENG Juchuang leading in future industry directions, showcasing Shenzhen's advantages in the new technological revolution and industrial transformation [2] - The "Robot Valley" in Nanshan, centered around companies like UBTECH and Huichuan Technology, has created an industrial ecosystem, with UBTECH's Walker S1 robot being utilized in factories of major companies like BYD and Geely [2] - Huichuan Technology, valued at nearly 200 billion yuan, has increased its R&D investment from 1.023 billion yuan to 3.147 billion yuan over the past five years, successfully developing key components for humanoid robots [2] Group 3 - Innovation is not limited to individual companies but is also evident in collaborative evolution across industries, exemplified by Shenzhen Hanno Medical's breakthrough in developing China's first ECMO system, set to enter the EU market in May 2025 [3] - Mindray Medical, a major shareholder of Hanno Medical, has played a crucial role in supporting its technological advancements, illustrating the model of larger companies fostering innovation in smaller firms within the industry chain [3]

Core Viewpoint - The recent trend of pharmaceutical companies applying for listings on the Hong Kong Stock Exchange (HKEX) is driven by a focus on innovation, with approximately 30 companies having submitted applications since the beginning of the year, including Jingxin Pharmaceutical, which aims to transition towards innovative drugs [1][3][5]. Group 1: Company Developments - Jingxin Pharmaceutical submitted its application for H-share listing on February 11, 2023, marking its entry into the A+H dual listing journey [3][4]. - The company specializes in two core disease areas: central nervous system diseases and cardiovascular diseases, and has shifted its focus from intermediates and raw materials to innovative drug development [3][4]. - For 2024, Jingxin Pharmaceutical projects total revenue of 4.159 billion yuan and a net profit of 719 million yuan, with R&D investment estimated at 384 million yuan [3]. Group 2: Industry Trends - The trend of pharmaceutical companies seeking listings in Hong Kong is characterized by a significant number of biotech firms, with 13 of the 30 applicants being unprofitable biotech companies [5][6]. - The HKEX's 18A chapter allows unprofitable biotech companies to list, providing them with opportunities for financing and enhancing their market presence [6][7]. - The A+H listing trend is notable, with companies like Baipusais, Dize Pharmaceutical, and Yifang Bio also applying for listings this year, indicating a broader movement among A-share companies to access international capital [8][9]. Group 3: Financial Insights - Baipusais expects a net profit of 160 to 190 million yuan for the previous year, reflecting a year-on-year growth of 29.21% to 53.43% [8]. - Dize Pharmaceutical anticipates a reduced loss of approximately 8.98% year-on-year, while Yifang Bio projects a net loss of 292 million yuan, indicating ongoing high R&D investments despite financial challenges [8][9]. Group 4: Market Implications - The influx of pharmaceutical companies into the HKEX is expected to enhance their capital structure and reduce financing costs, as the market tends to offer higher valuations for innovative drug companies [9]. - The competitive landscape may lead to a rapid differentiation in valuations, as companies will need to demonstrate commercial viability and clinical milestones post-listing [7].

香港交易及結算所有限公司、香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容 概不負責，對其準確性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、本公司的獨家保薦人、整體協調人、顧問或包銷團成員表示同意： Nanjing Novlead Biotechnology Co., Ltd. 南京諾令生物科技股份有限公司 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，本公 司不會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請 僅依據於香港公司註冊處處長註冊的本公司招股章程作出投資決定，招股章程的文本將於發售期內 ...

Core Viewpoint - The Sharjah Chamber of Commerce and Industry (SCCI) participated in the 2026 Sohar Investment Forum to enhance Sharjah's influence in regional and international economic platforms and to showcase its competitive advantages as a destination for foreign investment and strategic partnerships [1] Group 1: Forum Participation - The forum took place from February 4 to 5 in Sohar, Oman, attracting 929 representatives from 32 countries [1] - The participation aimed to build a platform for regional investment and business cooperation [1] Group 2: Investment Opportunities - The Sharjah delegation focused on investment opportunities in sectors such as food manufacturing, steel and mining, plastics, recycling, medical devices, aluminum, and heavy industrial support [1] - Bilateral meetings were held with various chambers of commerce, economic officials, and business representatives to promote Sharjah's free zone policies, industrial incentives, and infrastructure advantages [1] Group 3: Regional Collaboration - The initiative also aimed to foster industrial synergy and investment cooperation with Oman and surrounding markets [1]